Posted by Michael Wonder on 17 Jun 2026
RBI granted fast track designation by FDA, validating its direct to brain stem cell therapy for Alzheimer's disease
15 June 2026 - Regeneration Biomedical today announced that the US FDA has granted fast track designation to the company's investigational stem cell therapy for Alzheimer's disease.
The designation follows encouraging results from RBI's FDA cleared Phase I clinical trial in six patients with mild to moderate Alzheimer's disease.
